NEW YORK, April 28, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of U.S. Physical Therapy, Inc. securities (NYSE:USPH) from May 8, 2014 through March 16, 2017, inclusive (the “Class Period”) of the important May 30, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for U.S. Physical Therapy investors under the federal securities laws.
To join the U.S. Physical Therapy class action, go to http://rosenlegal.com/cases-1088.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) U.S. Physical Therapy had a material weakness in its internal controls over accounting and financial reporting; (2) U.S. Physical Therapy improperly accounted for redeemable non-controlling interests of acquired partnerships in violation of Generally Accepted Accounting Principles; (3) U.S. Physical Therapy’s financial statements for the years ended December 31, 2015 and 2014, and all quarters within 2014 and 2015, and the first three quarters of 2016 contained material errors; and (4) as a result, defendants’ statements about U.S. Physical Therapy’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 30, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1088.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 



